*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Significant relationship. Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention Peer Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Deepak L. Bhatt Official Reviewer AHA None None None AstraZeneca* Bristol-Myers Squibb* Eisai* Eli Lilly Ethicon* The Medicines Company* PLx Pharma Sanofi-aventis* None None Mauricio G. Cohen Official Reviewer AHA AstraZeneca* Momenta Pharma Xoma Terumo Medical None Invitrox* None None John P. Erwin III Official Reviewer ACCF/AHA Task Force on Performance Measures None None None None None None Kirk Garratt Official Reviewer SCAI Boston Scientific Cordis/Johnson & Johnson The Medicines Company Boston Scientific BMS/ sanofi-aventis* Daiichi-Sankyo/ Eli Lilly* Medtronic The Medicines Company Abbott Vascular Boston Scientific None None None Steven L. Goldberg Official Reviewer SCAI AGA Bristol-Myers Squibb Sanofi-aventis None None None Plaintiff, patient litigation, Alice K. Jacobs Official Reviewer ACCF/AHA Task Force on Practice Guidelines None None Wyeth* Abbott Vascular* Abiomed* Accumetrics* Cardiovascular Research Foundation (DSMB) Harvard Clinical Research Institute TIMI Study Group (DSMB) None None G.B. John Mancini Official Reviewer ACCF Board of Governors GlaxoSmithKline Merck Pfizer Sanofi-aventis None None Merck* None None (Continued) Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e645 Appendix 2. 